Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 safety trial of inhaled aztreonam (AZLI) in children with cystic fibrosis and chronic Pseudomonas aeruginosa infection
2011-001362-18Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2011
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aztreonam in cystic fibrosis (CF) and Pseudomonal infection, sponsored by Gilead Sciences. Primary endpoint: Study drug discontinuation due to safety or tolerability. Started Dec 2011; status: completed.
02
Drugs
aztreonam
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2011-001362-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001362-18.